Wall Street Just Punished Nvidia--Here's Why That Could Be a Huge Mistake
Warning! GuruFocus has detected 3 Warning Signs with NVDA.
Just look at the data. Taiwan Semiconductor (NYSE:TSM)Nvidia's main AI chip partnerreported a 43% jump in February sales. Foxconn, meanwhile, rolled out its FoxBrain AI platform with help from Nvidia's local supercomputing team. The growth levers are still turning. Melius Research's Ben Reitzes thinks so too. He's still calling NVDA a Buy, even as he trimmed his target to $170 from $195, citing short-term regulatory fog. At just 24.2x forward earnings (well below its 5-year average of 40x), the stock isn't priced like a company defining the next decade of computing.
All eyes now turn to Nvidia's GPU Technology Conference next week. CEO Jensen Huang is expected to map out the future: Blackwell Ultra, Rubin GPUs, an Arm-based CPU called Vera, and what's coming in 2027. Innovation's not slowingjust investor appetite. If Nvidia outlines a clear product pipeline and reaffirms long-term AI tailwinds, this selloff could look like a rare buying window in hindsight.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Coherent Eyes Core Growth Markets Following Defense Unit Sale
On Wednesday, Coherent Corp. (NYSE:COHR) agreed to sell its Aerospace and Defense business to Advent, a private equity investor, for $400 million. Proceeds will be used to reduce debt and will be immediately accretive to Coherent's EPS. Coherent's Aerospace and Defense designs and manufactures optical and laser systems for defense applications. The business includes approximately 550 employees and 10 geographic sites.'We are pleased to have reached this agreement with Advent. As part of our strategic portfolio optimization process, this transaction furthers our strategy to concentrate efforts on core growth markets and products,' said Jim Anderson, CEO of Coherent. The deal is expected to close in the current quarter. During the earnings call, Anderson said the decision to sell the business was made because it was not aligned with the company's long-term strategic focus areas and did not support long-term financial targets. View more earnings on COHR Coherent reported quarterly earnings of $1 per share, which beat the analyst consensus estimate of 91 cents. Revenue came in at $1.52 billion, which beat the analyst consensus estimate of $1.5 billion and is up from revenue of $1.31 billion from the same period last year. Outlook Coherent expects first-quarter revenue to be between $1.46 billion and $1.6 billion. On the earnings call, CEO Anderson said the current tariff policy remains unchanged from last quarter and is not expected to have a significant impact this quarter. 'Though we do not have full details yet, we believe President Trump's recent announcement regarding semiconductor tariffs may present a competitive advantage for our business,' Anderson noted. The semiconductor exemption covers many of the company's products, such as transceivers, and with U.S. manufacturing operations, the company expects it could avoid the semiconductor tariff. Analysts' Reaction Bank of America Securities downgraded Coherent from Buy to Neutral while raising its price forecast from $92 to $105. Needham reiterated its Buy rating with a $120 forecast, while Stifel also maintained a Buy but lifted its forecast from $100 to $118. Rosenblatt kept a Buy rating but trimmed its forecast from $150 to $135. Barclays maintained an Overweight stance and raised its forecast from $90 to $110. Price Action: COHR stock is trading lower by 23.47% to $87.25 at last check Thursday. Read Next:Image via Shutterstock Latest Ratings for COHR Date Firm Action From To Oct 2021 Stifel Reinstates Hold Sep 2021 Susquehanna Downgrades Positive Neutral Feb 2021 Benchmark Downgrades Buy Hold View More Analyst Ratings for COHR View the Latest Analyst Ratings UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? COHERENT (COHR): Free Stock Analysis Report This article Coherent Eyes Core Growth Markets Following Defense Unit Sale originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Why AI Robotics Stock Symbotic Surged 38.9% in July
Key Points More analysts are turning bullish on Symbotic after its Walmart deal. The stock has more than doubled in just six months. Symbotic shares could cool off a bit from here, but there's nothing to worry about. 10 stocks we like better than Symbotic › Symbotic (NASDAQ: SYM) stock has gone ballistic. A stunning rally of 38.9% in July drove the stock's half-yearly performance to a staggering 127.5%, according to data provided by S&P Global Market Intelligence. On Aug. 5, Symbotic hit a 52-week high of $64.16 per share. Symbotic automates warehouses and distribution centers with its artificial intelligence (AI)-powered robots and software. Symbotic's deal with Walmart (NYSE: WMT), in particular, has spurred massive investor interest in its stock, with several analysts upgrading their price targets in recent weeks. Why are analysts turning bullish on Symbotic stock? Analysts from Citi, Arete, Northland, and Oppenheimer were among those that initiated coverage or upgraded their price targets on Symbotic stock in July. While Arete has a price target of $50 per share on Symbotic, analysts from Northland raised their price target on the AI stock to $56 per share from $35 a share. Citi analyst Andrew Kaplowitz upped the stock's price target to $60 from $29 per share. Oppenheimer analyst Colin Rusch, meanwhile, raised Symbotic's price target from $35 per share to $54 a share in July, and then by another $5 in early August. In January, Symbotic acquired Walmart's advanced systems and robotics (ASR) business and signed a commercial agreement with the retail giant to deploy robotics automation systems for up to 400 accelerated pickup and delivery (APD) centers at Walmart stores over the next few years. Symbotic estimates incremental backlog of $5 billion from the deal. As news of Walmart testing "dark stores" to fulfill online orders hit the headlines in late June and through July, investors analysts bumped up their expectations from Symbotic stock and drove its price higher. Shares hit a new 52-week high of $64.16 ahead of earnings on Aug. 5. Could Symbotic stock lose momentum from here? Symbotic beat estimates with 26% year-over-year growth in revenue for its third quarter. Its net loss, however, widened to $32 million from $21 million a year ago because of restructuring charges. Moreover, the company's Q4 revenue guidance of $590 million to $610 million would mean only 4% year-over-year growth at the midpoint. Investors don't want to see a deceleration in sales from a growth stock that's yet to turn profitable. Yet investors should also look beyond the headlines. Symbotic is ready to deploy a next-generation storage system at warehouses that should significantly improve storage capacity and handling. The company, however, is facing startup problems, but expects them to be a temporary blip. Management insisted that none of it affects the company's backlog, which stands at a solid $22.4 billion today. To put that number into perspective, Symbotic generated revenue worth $1.8 billion last year. Long story short, Symbotic could face some quarters of slow revenue growth, but that shouldn't hurt the long-term growth potential of this AI and robotics stock. Should you invest $1,000 in Symbotic right now? Before you buy stock in Symbotic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Symbotic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,544!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,113,059!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Citigroup is an advertising partner of Motley Fool Money. Neha Chamaria has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Symbotic and Walmart. The Motley Fool has a disclosure policy. Why AI Robotics Stock Symbotic Surged 38.9% in July was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
22 minutes ago
- Business Wire
Philips Announces Plan for More Than USD 150 Million of New Investment in Manufacturing and R&D in the U.S. to Expand Production of AI-powered Health Technology Innovations
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Philips, a global leader in health technology, today announced a plan for new investments of more than USD 150 million in U.S. manufacturing and research and development (R&D). As part of today's announcement, Philips unveiled the expansion of its Reedsville, PA, manufacturing facility, which produces AI-enabled ultrasound systems for hospitals across the U.S. These investments come on top of Philips' annual USD 900 million R&D investment in the U.S. as well as investments in nearly 17,000 colleagues across 40 facilities in the United States. Philips has employees in every U.S. state supporting innovations used by clinicians and patients in 90% of hospitals across the country. The investment announced today by Philips includes the expansion of its Reedsville, PA, site and the recently announced expansion of Philips' Image Guided Therapy facility in Plymouth, MN. It also includes additional manufacturing and R&D projects which will come over the next several years to support the company's growth in the U.S. The Reedsville site, which currently manufactures transducers, will also customize the software and configurations of ultrasound systems for specific clinical procedures in cardiovascular, general and maternal care following the expansion. As an example, Philips' industry-leading CV ultrasound platform delivers advanced tools to help doctors diagnose structural heart and coronary artery disease quickly and confidently [1]. 'The proposed planned expansion of our manufacturing facilities is a demonstration of our deep commitment to the U.S. region,' said Jeff DiLullo, Chief Region Leader, Philips North America. 'Each year, Philips spends $900 million in R&D in the U.S. to drive innovation and deliver cutting-edge technology that empowers healthcare professionals to diagnose, treat and monitor patients more effectively. Increasing our manufacturing and R&D capabilities will create jobs and accelerate our ability to deliver better care for more people with innovative AI-enabled solutions.' The expansion of the Reedsville site is expected to add 24,000 square feet of manufacturing space in addition to 40,000 square feet of warehouse space and is expected to create 120 skilled manufacturing jobs. The recently announced expansion of Philips' image-guided therapy facility in Plymouth, MN, which includes the construction of a new medtech training center, is expected to create over 150 new jobs. [1] Philips ultrasound: The next dimension in echocardiography About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,300 employees with sales and services in more than 100 countries. News about Philips can be found at Forward-looking statements and other important information This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips' organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements. This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
